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Received October 25, 2012; accepted October 30, 2013AbstractBackground: Transarterial embolization of intracranial dural arteriovenous fistulas (DAVFs) is usually associated with inadequate embolization.
The purpose of this study was to report our experience of transarterial Onyx embolization of intracranial DAVFs with an emphasis on treatment
outcome with this new embolic agent in different types of DAVFs.
Methods: In the past 3 years, a total of 14 intracranial DAVFs have been treated by transarterial Onyx embolization. Among these, there were
nine males and five females, aged from 30 years to 82 years (mean ¼ 62 years). We retrospectively analyzed the injection volume and time of
Onyx embolization as well as outcomes in different types of DAVFs.
Results: The locations of the DAVFs were sigmoid sinus (n ¼ 6), tentorium (n ¼ 3), sinus confluence (n ¼ 2), transverseesigmoid sinus (n ¼ 1),
sigmoid sinusejugular bulb (n ¼ 1) and the superior petrous sinus (n ¼ 1). The mean volume and time of Onyx injection were 3.4 mL and 28
minutes, respectively (Cognard type I: 4.9 mL, 40 minutes; type II: 4.5 mL, 34 minutes; type III: 2.2 mL, 21 minutes; type IV: 2 mL, 22
minutes). Total fistula occlusion was achieved in six out of seven patients of type III and type IV DAVFs, and in four out of seven patients of type
I and type II DAVFs. Nine patients had total resolution of their symptoms, whereas partial regression occurred in five patients. No significant
periprocedural complication was found. Mean clinical follow-up period was 16 months.
Conclusion: Transarterial Onyx embolization of intracranial DAVFs is safe and effective. This technique is particularly useful in type III and type
IV DAVFs with a high cure rate, and lower volume of Onyx as well as a short injection time.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Intracranial dural arteriovenous fistulas (DAVFs) are un-
common lesions, comprising only 15% of all cerebrovascular
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drainage. Aggressive DAVFs with cortical venous drainage are
high-risk lesions usually presenting with nonhemorrhagic or
hemorrhagic neurological deficits.2,3 The goal of treatment of
aggressive DAVFs is total fistula occlusion. On the contrary,
benign DAVFs with antegrade dural sinus flow often present
with a seemingly benign course, such as pulsatile tinnitus, and
are typically managed by conservative or symptomatic treat-
ment. Since the advent of the Onyx, transarterial Onyx embo-
lization (TAOE) of DAVFs with morphologic cure has become
feasible4e8. However, the effect of TAOE in different types of
intracranial DAVFs has not yet been sufficiently evaluated.hinese Medical Association. All rights reserved.
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with TAOE involving intracranial DAVFs, highlighting the use
of this new embolic agent.
2. Methods
From February 2009 to August 2012, a series of 43 patients
with 49 intracranial DAVFs were referred to our institute for
endovascular embolization. Within this patient database, there
were 35 DAVFs (cavernous sinus DAVF ¼ 25, lateral dural
sinus¼ 10) that underwent transvenous coil packing. TAOEwas
performed on the other 14 DAVFs involving sinus confluence,
transverse, sigmoid sinus, or jugular bulb, or involving two lo-
cations. Final treatment decision regarding procedural access
routes and selection of embolic materials depended on
angioarchitecture analysis and hemodynamic of the DAVFs. If
the affected dural sinus was nonfunctional arising from venous
drainage or occlusion, we opted for transvenous coil packing.
By contrast, if the involved dural sinus was patent and/or
functional, TAOE was selected. Of these 14 patients, there were
nine males and five females, aged from 30 years to 82 years
(mean ¼ 62 years). Prior to initiation of this article, informed
consent was obtained from all 14 patients. The clinical mani-
festations were headache (n ¼ 4), cognitive decline (n ¼ 4),
tinnitus (n ¼ 4), intracerebral hemorrhage (n ¼ 2), facial
numbness (n¼ 1), limbweakness (n¼ 1), and seizure (n¼ 1), as
well as consciousness change (n ¼ 1).
TAOE procedures of the DAVFs were performed by a
transfemoral artery approach under general anesthesia. Sys-
temic intravenous heparinization was achieved by adminis-
tering an intravenous bolus of heparin (3000 International
Units). Activated clotting time measurements were performed
every 30 minutes during the procedure and clotting time was
maintained at a value that was approximately twice the
baseline. A 5- or 6-F guiding catheter was positioned in the
external carotid artery. An Onyx-compatible microcatheter
(Rebar, Echelon, or Marathon, ev3 Inc., Irvine, CA, USA) was
coaxially advanced into a feeding artery as close as possible to
the fistula site. We used Onyx-18, the least viscous prepara-
tion, for all patients. Onyx injection was performed according
to the plug-creating technique as mentioned in previously
published articles.4e7 Prior to Onyx embolization, the micro-
catheter lumen was flushed with dimethyl sulfoxide (DMSO,
ev3 Inc.). Then, Onyx was slowly injected into the parent
artery under a fluoroscopic monitor. When Onyx reflux
occurred, the injection was paused for 30 secondse2 minutes.
Usually, reflux may occur several times prior to Onyx
advancing into the fistula site. Once Onyx advanced to the
fistula site, it was slowly and continually injected. When the
Onyx cast stopped advancement, we used small and short
pulses of injection until the proximal draining veins were filled
and all feeders were retrograde filled by Onyx casts. During
the Onyx injection, digital subtraction angiography (DSA) was
performed to check the fistula flow and intracranial hemody-
namics. The end point of the procedure was complete fistula
occlusion or Onyx reflux longer than 3e4 cm to the micro-
catheter without evidence of further advancement of Onyx intothe fistula. An immediate post-embolization DSA was done
after the procedure was completed to check the occlusion of
the fistula. In terms of post-embolization follow-up, all pa-
tients were recommended to clinically follow-up every 1e2
months for 1 year. Imaging follow-up by magnetic resonance
imaging (MRI) and angiography (MRA) were recommended
every 6e12 months for 2 years and catheter angiography
annually for 2 years.
3. Results
The clinical findings and treatment outcome of the 14 pa-
tients are summarized in Table 1. The locations of the fistulas
were sigmoid sinus (n ¼ 6, Fig. 1), tentorium (n ¼ 3, Fig. 2),
sinus confluence (n ¼ 2), transverseesigmoid sinus (n ¼ 1),
sigmoid sinusejugular bulb (n ¼ 1), and superior petrous sinus
(n ¼ 1). Regarding the type of DAVFs that were observed,
Cognard type IB was found in two patients, type IIA in one
patient, type IIAþB in five patients (Fig. 1), type III in four
patients, and type IV in three patients (Fig. 2). All DAVFs were
embolized in a single session. Single feeder injection was per-
formed in 11 patients, whereas three patients underwent two-
feeder injections. The injection feeding pedicle was the occip-
ital artery (n¼ 11), middlemeningeal artery (MMA, n¼ 5) and/
or ascending pharyngeal artery (n ¼ 1). The mean volume and
injection time of Onyx were 3.4 mL and 28 minutes, respec-
tively. In terms of mean volume/time of injection of individual
DAVFs, type I was in 4.9 mL/40 minutes, type II was 4.5 mL/34
minutes, type III was in 2.2 mL/21 minutes, and type IV was in
2 mL/22 minutes (Table 2). In 12 cases, removal of the micro-
catheter was uneventful; in two patients with longer injection
time (45 minutes, 38 minutes) with long segments of Onyx
reflux (4 cm, 3.5 cm), asymptomatic disruption and retention of
the distal segment of the microcatheter to feeders of external
carotid arteries were found. Complete fistula occlusion was
achieved in 10 patients (Figs. 1 and 2), whereas partial embo-
lization occurred in four patients. Of the four partial emboli-
zations, two were type IIAþB, and after embolization one was
regraded to type IIA. Another one was regraded to type IA; an
additional two patients underwent radiosurgery (GammaKnife)
and one was cured by the 24-month follow-up, whereas one
patient was still waiting for the effect of radiosurgery. Regres-
sive clinical manifestation was found in all patients, with
complete regression in eight patients and partial regression in
six patients. No significant procedure-related neurological
complications, such as intracranial hemorrhage or infarction or
cranial nerve impairment, were observed in any of the 14 pa-
tients. No recurrent or new DAVFs were demonstrated in the
follow-up MRI/MRA (n¼ 12). Only one patient had follow-up
DSA and showed no evidence of recurrent DAVFs. All patients
were clinically followed up for an average of 16 months
(range ¼ 6e36 months).
4. Discussion
Previous series have shown that the cure rate of DAVFs
varied from 62.5% to 100% by TAOE.4e8 The injection time
Table 1
Demographic and clinical outcomes in 14 patients with intracranial DAVFs after transarterial Onyx embolization.
Patient/sex/
age (y)
Clinical manifestations Cognard
DAVF
grading
DAVF location Injection
artery
Volume
of Onyx
injection
(mL)
Injection
time (min)
Angiographic
outcome
Complication Clinical
follow-up
(mo)
1/M/37 Headache, dizziness,
pulsatile tinnitus
IIAþB Sigmoid sinus OA 5.1 30 Morphologic
cure
Nil 11
2/M/82 Cognitive decline III Sinus confluence OA 2.8 13 Morphologic
cure
Nil 5
3/M/58 Facial numbness IV Tentorium MMA 1.4 19 Morphologic
cure
Nil 8
4/M/79 Tinnitus III Sigmoid sinus OA 3 25 Morphologic
cure
Nil 19
5/M/30 Tinnitus IIA Sigmoid sinus OA 3.5 39 Morphologic
cure
Nil 14
6/M/58 Limb weakness IV Tentorium MMA 2.9 22 Morphologic
cure
Nil 10
7/F/73 Cognitive decline IIAþB Sigmoid sinus OA 3.4 31 Morphologic
cure
Nil 15
8/F/68 Headache III Transverseesigmoid
sinus
MMA 0.8 16 Morphologic
cure
Nil 24
9/M/49 Conscious change,
ICH
IV Superior petrous
sinus
MMA, OA 1.8 25 Partial
embolization
Nil 24
10/F/74 Headache, pulsatile
tinnitus
IB Sigmoid sinus,
Jugular bulb
APA, OA 5.6 38 Morphologic
cure
Catheter
disruption
17
11/F/65 Headache IB Sigmoid sinus OA 4.2 42 Partial
embolization
Nil 12
12/M/75 Cognitive decline,
ICH
IIAþB Sigmoid sinus OA 2.8 25 Partial
embolization
Nil 31
13/M/73 Cognitive decline IIAþB Sinus confluence Bilateral OA 7.5 45 Partial
embolization
Catheter
disruption
24
14/F/48 Seizure III Tentorium MMA 2.1 28 Morphologic
cure
Nil 6
APA ¼ ascending pharyngeal artery; DAVF ¼ dural arteriovenous fistula; ICH ¼ intracerebral hemorrhage; MMA ¼ middle meningeal artery; OA ¼ occipital
artery.
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fistula occlusion was achieved in 10 out of 14 patients (71%),
which is comparable with previously reported outcomes;
particularly, in type III and type IV DAVFs, in which six out of
seven DAVFs were cured. One failure to achieve total fistula
occlusion was presumed to be insufficient reflux of Onyx
because of inexperience in the first case of this series. On the
contrary, in seven DAVFs with type I and type II, only four
fistulas achieved total occlusion. Relatively, the lower cure rate
was assumed to be due to more dural feeders and larger fistula
flow than those in type III and type IV. Another factor is the aim
of TAOE to embolize the fistula retaining affected sinus patency,
particularly in type I, or to reverse aggressive DAVFs to more
benign behavior. We usually stop the procedure when Onyx
advances to sinus after many attempts. Regarding the injection
volume and TAOE time, these were largely dependent on the
number of feeders and fistula flow. In our series, the mean vol-
ume and time of Onyx injection in type I and type II are
significantly higher than those in type III and type IV (4.6mLvs.
2.1 mL, 36 minutes vs. 21 minutes, respectively). These results
were attributed tomore dural feeders, larger fistula flow in type I
and type II than those in type III and type IV.
The definitive treatment of DAVFs requires the occlusion of
the arteriovenous shunt without interfering with the normal
venous drains. The treatment can be performed byconventional open neurosurgery, radiosurgery, or endovascular
embolization. The main goal of endovascular treatment of
DAVFs is total fistula occlusion or the elimination of high-risk
features such as cortical vein drains or symptomatic treatment
in benign DAVFs. In the past, to achieve an angiographic-
proven cure with complete fistula occlusion, a transvenous
approach with coil packing of affected dural sinus was
selected. This technique is appropriate as long as the diseased
segment of the sinus is occluded completely or does not
participate in normal venous return. However, transvenous
embolization is not always possible in cases with difficult
fistula anatomy such as in isolated or high-grade stenotic dural
sinus.9,10 Transarterial approaches consist of superselective
catheterization of the dural branches supplying the DAVF and
by delivering the embolic agent (e.g., liquid adhesives or
particles). However, the angiographic cure rate is low owing to
numerous arterial feeders and the limited volume of injection
of embolic materials.11
Onyx, a nonadhesive liquid embolic material, was initially
introduced to treat brain arteriovenous malformation in 1999.
In 2006, the first case of a DAVF successfully occluded by
Onyx was reported.12 Subsequently, other case reports and
case series were published.6e10,13 We started to use Onyx to
embolize DAVFs in 2009; prior to this, we had several expe-
riences with Onyx to embolize brain arteriovenous
Fig. 2. A 58-year-old male had lower limb weakness. (A,B) Left carotid angiography revealed Cognard type IV dural arteriovenous fistulas (DAVFs) in the left
tentorium fed by the middle meningeal artery and meningohypophyseal trunk with deep venous reflux associated with venous pouch. (CeE) Post-embolization
angiography demonstrated Onyx cast with total occlusion of the DAVFs. The total volume and injection time of Onyx were 2.9 mL and 22 minutes, respectively.
Fig. 1. A 37-year-old male had headache, dizziness, and pulsatile tinnitus. (A, B) Left carotid angiography revealed Cognard type II AþB dural arteriovenous
fistulas (DAVFs) at the left sigmoid sinus mainly supplied by the occipital artery with retrograde reflux to the dural sinus and cortical vein. (CeE) Post-
embolization angiography demonstrated Onyx cast with total occlusion of the DAVFs. The total volume and injection time of Onyx were 5.1 mL and 30 mi-
nutes, respectively.
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Table 2
Mean volume and injection time of transarterial Onyx embolization in
different types of DAVFs.
Type and number of DAVFs Volume (mL) Time (min)
Type I (n ¼ 2) 4.9 40
Type II (n ¼ 5) 4.5 34
Type III (n ¼ 4) 2.2 21
Type IV (n ¼ 3) 2 22
Mean 3.4 28
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presentations, and most of the DAVFs were located in the
lateral dural sinuses. We attempted to occlude the fistula with
the goal of preserving sinus patency and function.
Regarding the Onyx injection technique, the microcatheter
tip should be navigated into a dural feeder as close to the fistula
as possible. Usually, reflux is slowly built up with a 1e3-minute
pause between injection attempts until the feeding artery is
plugged. Then Onyx starts to advance into the fistula and
draining veins. Sometimes from five to 15 attempts are needed
prior toOnyx advancing.When amicrocatheter is inserted into a
branch of the external carotid artery, reflux of Onyx of 3e4 cm
to the feeder can be accepted, although Onyx does not react with
or stick to the vessel wall. After injections of longer than 30e40
minutes with a long segment of reflux, the microcatheter may be
difficult to retrieve completely. In our series, there were two
occasions of breaking and retention of a distal microcatheter
into a feeder of the occipital arteries during retrieval, which
were associated with greater than 35minute injections andmore
than 3 cm reflux. Fortunately, there was no significant arterial
injury such as dissection, rupture, or brain ischemia.
There are several advantages of TAOE in DAVFs. The main
advantage is the ability to deliver a large volume of Onyx
during a prolonged injection through a single pedicle.6e10 The
diffusion properties of the agent allow progressive filling of
the arteriovenous network and veins with artery-to-artery
retrograde migration of the agent. In many of our cases, a
substantial portion of the lesion could be embolized from a
single arterial injection because the agent successfully pene-
trated the depths of the fistula and then flowed into other
arterial feeders. Onyx also offers the possibility of venous
sinus packing/occlusion from an arterial side approach, which
may be very helpful in cases with isolated dural sinus. The
potential to backfill multiple feeding arteries from a single
arterial injection is critical to the hypothesis that DAVFs may
be cured by arterial embolization alone with the use of Onyx.
However, Onyx embolization is associated with several dis-
advantages.14 In very high-flow lesions or large-diameter
vessels, Onyx, similar to any embolic agent, can migrate
into the veins and embolize to the lungs resulting in a pul-
monary embolism. Therefore, high-concentrated N-butyl
cyanoacrylate (NBCA) or detachable coils may be more
appropriate in those high-flow fistulas. Another consideration
is the excess radiation exposure due to prolonged fluoroscopic
duration.
Previous studies have shown that MMA is the most com-
mon route for Onyx injection and it can be readily catheterizedto a distal position.6e8 Long segments of arterial reflux can be
accepted because microcatheter removal proved to be easy in
such cases. However, ischemic injury to the trigeminal and
facial nerve may occur with excessive proximal arterial reflux
of Onyx beyond the foramen spinosum.9 Inadvertent emboli-
zation of the ophthalmic artery leading to loss of visual acuity
may occur via dangerous anastomosis. Therefore, the common
complications of TAOE are related to MMA injection and
include cardiac Onyx migration, reflexive bradyarrhythmia,
transient visual hallucination, and transient or permanent
cranial nerve palsy. Such complications may occur in up to
24e31% of patients undergoing TAOE.9,11 Permanent neuro-
logical complications such as intracranial hemorrhage or
ischemia are rare and occur in approximately 4e5% of pa-
tients.6,13 In our series, we selected the occipital artery for
Onyx embolization in 65% of feeding pedicle for injection,
largely because most DAVFs were located in the posterior
fossa and primarily fed by occipital artery. Another advantage
of trans-occipital artery embolization is the comparative safety
of the procedure when compared with trans-MMA, owing to
the reduced risk of cranial palsy or through dangerous anas-
tomosis to embolize pial vessels. The disadvantage of trans-
occipital artery embolization is that most occipital arteries
are tortuous and more difficult to catheterize; however,
meticulous manipulation of the microcatheter with successful
navigation of the microcatheter to the ideal site can usually be
achieved in the majority of cases. In our initial experiences,
there were no significant periprocedural complications.
In conclusion, although there was a lack of DSA follow-up,
our initial experience shows that treatment of DAVFs by
TAOE is effective and safe. This technique allows for the
complete occlusion of the DAVFs in a single session in most
cases. This technique is particularly useful in those DAVFs
with Cognard type III and type IV owing to the lower volume
of Onyx, short injection time, and high cure rate.
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